BRTX Insider Trading

Insider Ownership Percentage: 21.60%
Insider Buying (Last 12 Months): $206,026.92
Insider Selling (Last 12 Months): $995.42

BioRestorative Therapies Insider Trading History Chart

This chart shows the insider buying and selling history at BioRestorative Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioRestorative Therapies Share Price & Price History

Current Price: $1.67
Price Change: Price Decrease of -0.01 (-0.60%)
As of 07/18/2024 01:00 AM ET

This chart shows the closing price history over time for BRTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BioRestorative Therapies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2024Francisco SilvaVPBuy1,708$1.16$1,981.28149,159View SEC Filing Icon  
2/9/2024Dale BroadrickMajor ShareholderBuy86,041$1.32$113,574.12477,972View SEC Filing Icon  
2/7/2024Dale BroadrickMajor ShareholderBuy36,374$1.38$50,196.12363,419View SEC Filing Icon  
12/1/2023Dale BroadrickMajor ShareholderSell250$1.88$470.00327,045View SEC Filing Icon  
11/27/2023Dale BroadrickMajor ShareholderSell278$1.89$525.42327,295View SEC Filing Icon  
9/15/2023Lance AlstodtCEOBuy2,200$1.70$3,740.00189,505View SEC Filing Icon  
9/14/2023Dale BroadrickMajor ShareholderBuy10,000$1.54$15,400.00317,573View SEC Filing Icon  
9/13/2023Lance AlstodtCEOBuy800$1.53$1,224.00188,105View SEC Filing Icon  
9/7/2023Dale BroadrickMajor ShareholderBuy1,000$1.81$1,810.00307,573View SEC Filing Icon  
9/6/2023Lance AlstodtCEOBuy2,887$1.96$5,658.52187,305View SEC Filing Icon  
8/31/2023Francisco SilvaVPBuy4,954$2.22$10,997.88164,644View SEC Filing Icon  
7/28/2023Dale BroadrickMajor ShareholderBuy500$2.89$1,445.00306,573View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for BioRestorative Therapies (NASDAQ:BRTX)

69.38% of BioRestorative Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

BioRestorative Therapies Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/1/2024StoneX Group Inc.34,850$48K0.0%N/A0.515%Search for SEC Filing on Google Icon
11/1/2023Lynwood Capital Management Inc.20,000$36K0.1%N/A0.428%Search for SEC Filing on Google Icon
10/10/2023FNY Investment Advisers LLC14,665$26K0.0%N/A0.314%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BioRestorative Therapies logo
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Read More on BioRestorative Therapies

Today's Range

Now: $1.67
Low: $1.65
High: $1.72

50 Day Range

MA: $1.61
Low: $1.16
High: $2.22

52 Week Range

Now: $1.67
Low: $1.03
High: $3.67

Volume

37,930 shs

Average Volume

1,223,445 shs

Market Capitalization

$11.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

63.43

Who are the company insiders with the largest holdings of BioRestorative Therapies?

BioRestorative Therapies' top insider shareholders include:
  1. Dale Broadrick (Major Shareholder)
  2. Lance Alstodt (CEO)
  3. Francisco Silva (VP)
Learn More about top insider investors at BioRestorative Therapies.